IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤内科
学科主题临床医学
Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma
Zhu, Bu-Dong1,2; Yuan, Shou-Jun3; Zhao, Qi-Cheng1,2; Li, Xin1,2; Li, Yan1,2; Lu, Qi-Ying1,2
关键词Neoplasms Gefitinib Therapy carcinoma Hepatocellular cisplatin
刊名WORLD JOURNAL OF GASTROENTEROLOGY
2005-03-07
11期:9页:1382-1386
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
英文摘要

AIM: To investigate the inhibitory effect of gefitinib combined with cytotoxic agent cisplatin (CDDP) on hepatocellular carcinoma (HCC).

METHODS: Female Kunming mice and H22 hepatocarcinoma cells were used. Gefitinib at daily dose of 100 mg/kg body weight (BW) or lecithin liquid was given by gastrogavage once a day for 5 or 10 successive days. CDDP or normal saline (NS) was administered intraperitoneally (i.p.) once a day for 5 successive days. Mice were randomly divided into control group (lecithin, or NS, i.p.), CDDP group (daily dose, 1.2 mg/kg BW; d1-5, or d6-10), Gefitinib (d1-5, or d6-10, or d1-10), and Gefitinib combined with CDDP groups. The inhibitory rate (IR) of tumor, net BW, spleen index (SI), thymus index (TI) and the amount of peripheral blood cells of mice were detected on the 12th experiment day.

RESULTS: The growth of HCC in mice was inhibited by Gefitinib alone (IR: 41% in d1-10 group and 30% in d1-5 group, respectively) or CDDP alone (IR: 32-54% in d1-5 group or d6-10 group). The highest inhibitory effect (IR: 56%) on HCC growth was observed in Gefitinib (d1-10) combined with CDDP (d1-5) group. Higher inhibition was also observed in CDDP (d1-5) followed by Gefitinib (d6-10) group than that in Gefitinib (d1-5) followed by CDDP (d6-10) group (IR: 61% vs 36%, P < 0.01) in the independent study. Net BW, SI, TI and the amount of blood cells of mice in Gefitinib alone group were not significantly different from those in control groups.

CONCLUSION: Gefitinib can significantly inhibit the growth of murine H22 hepatocellular carcinoma. If Gefitinib is used after CDDP treatment in animal experiments, the inhibitory effect could be enhanced. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.

语种英语
WOS记录号WOS:000208101400021
引用统计
被引频次:18[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63274
专题北京大学临床肿瘤学院_肿瘤内科
北京大学临床肿瘤学院_乳腺肿瘤内科
作者单位1.Peking Univ, Sch Oncol, Dept Med Oncol, Beijing 100036, Peoples R China
2.Beijing Canc Hosp, Beijing Inst Canc Res, Beijing 100036, Peoples R China
3.Acad Mil Med Sci, Inst Radiat Med, Beijing 100850, Peoples R China
推荐引用方式
GB/T 7714
Zhu, Bu-Dong,Yuan, Shou-Jun,Zhao, Qi-Cheng,et al. Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2005,11(9):1382-1386.
APA Zhu, Bu-Dong,Yuan, Shou-Jun,Zhao, Qi-Cheng,Li, Xin,Li, Yan,&Lu, Qi-Ying.(2005).Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.WORLD JOURNAL OF GASTROENTEROLOGY,11(9),1382-1386.
MLA Zhu, Bu-Dong,et al."Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma".WORLD JOURNAL OF GASTROENTEROLOGY 11.9(2005):1382-1386.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhu, Bu-Dong]的文章
[Yuan, Shou-Jun]的文章
[Zhao, Qi-Cheng]的文章
百度学术
百度学术中相似的文章
[Zhu, Bu-Dong]的文章
[Yuan, Shou-Jun]的文章
[Zhao, Qi-Cheng]的文章
必应学术
必应学术中相似的文章
[Zhu, Bu-Dong]的文章
[Yuan, Shou-Jun]的文章
[Zhao, Qi-Cheng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。